EMG
ELOS

Ellington Management Group’s Syneron Medical Ltd ELOS Stock Holding History

Ellington Management Group’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,900
Closed -$358K – 1026
2015
Q1 		$358K Buy
+28,900
New +$320K 0.07% 401

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Ellington Management Group's ELOS Position: Q2 2015 in Review

Ellington Management Group sold out of Syneron Medical Ltd (ELOS) in Q2 2015, closing a stake of 28,900 shares — an estimated $358K sold.

Ellington Management Group first reported a position in ELOS in Q1 2015 and held it in 1 quarter. The position peaked at $358K in Q1 2015. 79 funds tracked by Wall St. Rank hold ELOS as of Q2 2015.

  • Ellington Management Group reported no remaining Syneron Medical Ltd position as of Q2 2015 after selling out during the quarter.
  • Ellington Management Group sold 28,900 Syneron Medical Ltd shares in Q2 2015, an estimated $358K.
  • Ellington Management Group first reported a position in Syneron Medical Ltd in Q1 2015 and held it in 1 quarter.
  • Ellington Management Group's Syneron Medical Ltd position peaked at $358K in Q1 2015.
  • 79 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2015.

Based on Ellington Management Group's 13F filing for Q2 2015, filed 14 Aug 2015.